Report cover image

Global Tuberculosis Vaccine Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 194 Pages
SKU # APRC20359529

Description

Summary

According to APO Research, the global Tuberculosis Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Tuberculosis Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Tuberculosis Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Tuberculosis Vaccine market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Tuberculosis Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Tuberculosis Vaccine market include AJ Vaccines, Ataulpho de Paiva, BioFarma, Biomed Lublin, GreenSignal Bio Pharma, IVAC, Japan BCG Lab, Microgen and Queen Saovabha Mem. Inst, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Tuberculosis Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Tuberculosis Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Tuberculosis Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Tuberculosis Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Tuberculosis Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Tuberculosis Vaccine sales, projected growth trends, production technology, application and end-user industry.

Tuberculosis Vaccine Segment by Company

AJ Vaccines
Ataulpho de Paiva
BioFarma
Biomed Lublin
GreenSignal Bio Pharma
IVAC
Japan BCG Lab
Microgen
Queen Saovabha Mem. Inst
Serum Institute of India
Taj Pharmaceuticals
Merck
China National Biotec
Tuberculosis Vaccine Segment by Type

Immune Vaccine
Therapy Vaccine
Tuberculosis Vaccine Segment by Application

Self-Procurement
UNICEF
Other
Tuberculosis Vaccine Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Tuberculosis Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Tuberculosis Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Tuberculosis Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Tuberculosis Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tuberculosis Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tuberculosis Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tuberculosis Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tuberculosis Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tuberculosis Vaccine industry.
Chapter 3: Detailed analysis of Tuberculosis Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Tuberculosis Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Tuberculosis Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Table of Contents

194 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Tuberculosis Vaccine Sales Value (2020-2031)
1.2.2 Global Tuberculosis Vaccine Sales Volume (2020-2031)
1.2.3 Global Tuberculosis Vaccine Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Tuberculosis Vaccine Market Dynamics
2.1 Tuberculosis Vaccine Industry Trends
2.2 Tuberculosis Vaccine Industry Drivers
2.3 Tuberculosis Vaccine Industry Opportunities and Challenges
2.4 Tuberculosis Vaccine Industry Restraints
3 Tuberculosis Vaccine Market by Company
3.1 Global Tuberculosis Vaccine Company Revenue Ranking in 2024
3.2 Global Tuberculosis Vaccine Revenue by Company (2020-2025)
3.3 Global Tuberculosis Vaccine Sales Volume by Company (2020-2025)
3.4 Global Tuberculosis Vaccine Average Price by Company (2020-2025)
3.5 Global Tuberculosis Vaccine Company Ranking (2023-2025)
3.6 Global Tuberculosis Vaccine Company Manufacturing Base and Headquarters
3.7 Global Tuberculosis Vaccine Company Product Type and Application
3.8 Global Tuberculosis Vaccine Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Tuberculosis Vaccine Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Tuberculosis Vaccine Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Tuberculosis Vaccine Market by Type
4.1 Tuberculosis Vaccine Type Introduction
4.1.1 Immune Vaccine
4.1.2 Therapy Vaccine
4.2 Global Tuberculosis Vaccine Sales Volume by Type
4.2.1 Global Tuberculosis Vaccine Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Tuberculosis Vaccine Sales Volume by Type (2020-2031)
4.2.3 Global Tuberculosis Vaccine Sales Volume Share by Type (2020-2031)
4.3 Global Tuberculosis Vaccine Sales Value by Type
4.3.1 Global Tuberculosis Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Tuberculosis Vaccine Sales Value by Type (2020-2031)
4.3.3 Global Tuberculosis Vaccine Sales Value Share by Type (2020-2031)
5 Tuberculosis Vaccine Market by Application
5.1 Tuberculosis Vaccine Application Introduction
5.1.1 Self-Procurement
5.1.2 UNICEF
5.1.3 Other
5.2 Global Tuberculosis Vaccine Sales Volume by Application
5.2.1 Global Tuberculosis Vaccine Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Tuberculosis Vaccine Sales Volume by Application (2020-2031)
5.2.3 Global Tuberculosis Vaccine Sales Volume Share by Application (2020-2031)
5.3 Global Tuberculosis Vaccine Sales Value by Application
5.3.1 Global Tuberculosis Vaccine Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Tuberculosis Vaccine Sales Value by Application (2020-2031)
5.3.3 Global Tuberculosis Vaccine Sales Value Share by Application (2020-2031)
6 Tuberculosis Vaccine Regional Sales and Value Analysis
6.1 Global Tuberculosis Vaccine Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Tuberculosis Vaccine Sales by Region (2020-2031)
6.2.1 Global Tuberculosis Vaccine Sales by Region: 2020-2025
6.2.2 Global Tuberculosis Vaccine Sales by Region (2026-2031)
6.3 Global Tuberculosis Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Tuberculosis Vaccine Sales Value by Region (2020-2031)
6.4.1 Global Tuberculosis Vaccine Sales Value by Region: 2020-2025
6.4.2 Global Tuberculosis Vaccine Sales Value by Region (2026-2031)
6.5 Global Tuberculosis Vaccine Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Tuberculosis Vaccine Sales Value (2020-2031)
6.6.2 North America Tuberculosis Vaccine Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Tuberculosis Vaccine Sales Value (2020-2031)
6.7.2 Europe Tuberculosis Vaccine Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Tuberculosis Vaccine Sales Value (2020-2031)
6.8.2 Asia-Pacific Tuberculosis Vaccine Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Tuberculosis Vaccine Sales Value (2020-2031)
6.9.2 South America Tuberculosis Vaccine Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Tuberculosis Vaccine Sales Value (2020-2031)
6.10.2 Middle East & Africa Tuberculosis Vaccine Sales Value Share by Country, 2024 VS 2031
7 Tuberculosis Vaccine Country-level Sales and Value Analysis
7.1 Global Tuberculosis Vaccine Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Tuberculosis Vaccine Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Tuberculosis Vaccine Sales by Country (2020-2031)
7.3.1 Global Tuberculosis Vaccine Sales by Country (2020-2025)
7.3.2 Global Tuberculosis Vaccine Sales by Country (2026-2031)
7.4 Global Tuberculosis Vaccine Sales Value by Country (2020-2031)
7.4.1 Global Tuberculosis Vaccine Sales Value by Country (2020-2025)
7.4.2 Global Tuberculosis Vaccine Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.5.2 USA Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.6.2 Canada Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.8.2 Germany Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.9.2 France Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.9.3 France Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.11.2 Italy Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.12.2 Spain Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.13.2 Russia Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.16.2 China Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.16.3 China Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.17.2 Japan Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.19.2 India Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.19.3 India Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.20.2 Australia Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.24.2 Chile Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.26.2 Peru Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.28.2 Israel Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.29.2 UAE Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.31.2 Iran Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Tuberculosis Vaccine Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Tuberculosis Vaccine Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Tuberculosis Vaccine Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 AJ Vaccines
8.1.1 AJ Vaccines Comapny Information
8.1.2 AJ Vaccines Business Overview
8.1.3 AJ Vaccines Tuberculosis Vaccine Sales, Value and Gross Margin (2020-2025)
8.1.4 AJ Vaccines Tuberculosis Vaccine Product Portfolio
8.1.5 AJ Vaccines Recent Developments
8.2 Ataulpho de Paiva
8.2.1 Ataulpho de Paiva Comapny Information
8.2.2 Ataulpho de Paiva Business Overview
8.2.3 Ataulpho de Paiva Tuberculosis Vaccine Sales, Value and Gross Margin (2020-2025)
8.2.4 Ataulpho de Paiva Tuberculosis Vaccine Product Portfolio
8.2.5 Ataulpho de Paiva Recent Developments
8.3 BioFarma
8.3.1 BioFarma Comapny Information
8.3.2 BioFarma Business Overview
8.3.3 BioFarma Tuberculosis Vaccine Sales, Value and Gross Margin (2020-2025)
8.3.4 BioFarma Tuberculosis Vaccine Product Portfolio
8.3.5 BioFarma Recent Developments
8.4 Biomed Lublin
8.4.1 Biomed Lublin Comapny Information
8.4.2 Biomed Lublin Business Overview
8.4.3 Biomed Lublin Tuberculosis Vaccine Sales, Value and Gross Margin (2020-2025)
8.4.4 Biomed Lublin Tuberculosis Vaccine Product Portfolio
8.4.5 Biomed Lublin Recent Developments
8.5 GreenSignal Bio Pharma
8.5.1 GreenSignal Bio Pharma Comapny Information
8.5.2 GreenSignal Bio Pharma Business Overview
8.5.3 GreenSignal Bio Pharma Tuberculosis Vaccine Sales, Value and Gross Margin (2020-2025)
8.5.4 GreenSignal Bio Pharma Tuberculosis Vaccine Product Portfolio
8.5.5 GreenSignal Bio Pharma Recent Developments
8.6 IVAC
8.6.1 IVAC Comapny Information
8.6.2 IVAC Business Overview
8.6.3 IVAC Tuberculosis Vaccine Sales, Value and Gross Margin (2020-2025)
8.6.4 IVAC Tuberculosis Vaccine Product Portfolio
8.6.5 IVAC Recent Developments
8.7 Japan BCG Lab
8.7.1 Japan BCG Lab Comapny Information
8.7.2 Japan BCG Lab Business Overview
8.7.3 Japan BCG Lab Tuberculosis Vaccine Sales, Value and Gross Margin (2020-2025)
8.7.4 Japan BCG Lab Tuberculosis Vaccine Product Portfolio
8.7.5 Japan BCG Lab Recent Developments
8.8 Microgen
8.8.1 Microgen Comapny Information
8.8.2 Microgen Business Overview
8.8.3 Microgen Tuberculosis Vaccine Sales, Value and Gross Margin (2020-2025)
8.8.4 Microgen Tuberculosis Vaccine Product Portfolio
8.8.5 Microgen Recent Developments
8.9 Queen Saovabha Mem. Inst
8.9.1 Queen Saovabha Mem. Inst Comapny Information
8.9.2 Queen Saovabha Mem. Inst Business Overview
8.9.3 Queen Saovabha Mem. Inst Tuberculosis Vaccine Sales, Value and Gross Margin (2020-2025)
8.9.4 Queen Saovabha Mem. Inst Tuberculosis Vaccine Product Portfolio
8.9.5 Queen Saovabha Mem. Inst Recent Developments
8.10 Serum Institute of India
8.10.1 Serum Institute of India Comapny Information
8.10.2 Serum Institute of India Business Overview
8.10.3 Serum Institute of India Tuberculosis Vaccine Sales, Value and Gross Margin (2020-2025)
8.10.4 Serum Institute of India Tuberculosis Vaccine Product Portfolio
8.10.5 Serum Institute of India Recent Developments
8.11 Taj Pharmaceuticals
8.11.1 Taj Pharmaceuticals Comapny Information
8.11.2 Taj Pharmaceuticals Business Overview
8.11.3 Taj Pharmaceuticals Tuberculosis Vaccine Sales, Value and Gross Margin (2020-2025)
8.11.4 Taj Pharmaceuticals Tuberculosis Vaccine Product Portfolio
8.11.5 Taj Pharmaceuticals Recent Developments
8.12 Merck
8.12.1 Merck Comapny Information
8.12.2 Merck Business Overview
8.12.3 Merck Tuberculosis Vaccine Sales, Value and Gross Margin (2020-2025)
8.12.4 Merck Tuberculosis Vaccine Product Portfolio
8.12.5 Merck Recent Developments
8.13 China National Biotec
8.13.1 China National Biotec Comapny Information
8.13.2 China National Biotec Business Overview
8.13.3 China National Biotec Tuberculosis Vaccine Sales, Value and Gross Margin (2020-2025)
8.13.4 China National Biotec Tuberculosis Vaccine Product Portfolio
8.13.5 China National Biotec Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Tuberculosis Vaccine Value Chain Analysis
9.1.1 Tuberculosis Vaccine Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Tuberculosis Vaccine Sales Mode & Process
9.2 Tuberculosis Vaccine Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Tuberculosis Vaccine Distributors
9.2.3 Tuberculosis Vaccine Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.